KEB Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-600
Closed -$34.6K – 100
2026
Q2
$34.6K Buy
+600
New +$34.5K 0.01% 114
2024
Q2
– Sell
-4,300
Closed -$233K – 71
2024
Q1
$233K Hold
4,300
– – 0.08% 63
2023
Q4
$221K Hold
4,300
– – 0.08% 64
2023
Q3
$250K Hold
4,300
– – 0.1% 52
2023
Q2
$275K Hold
4,300
– – 0.11% 47
2023
Q1
$298K Hold
4,300
– – 0.13% 44
2022
Q4
$309K Sell
4,300
-24
-0.6% -$1.81K 0.16% 42
2022
Q3
$307K Buy
4,324
+24
+0.6% +$1.74K 0.2% 37
2022
Q2
$331K Buy
+4,300
New +$327K 0.21% 34
2022
Q1
– Sell
-4,552
Closed -$284K – 45
2021
Q4
$284K Buy
+4,552
New +$267K 0.18% 38

Other funds holding BMY

KEB Asset Management's BMY Position: Q3 2026 in Review

KEB Asset Management sold out of Bristol-Myers Squibb (BMY) in Q3 2026, closing a stake of 600 shares — an estimated $34.6K sold.

KEB Asset Management first reported a position in BMY in Q4 2021 and held it in 10 quarters. The position peaked at $331K in Q2 2022. 2,561 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • KEB Asset Management reported no remaining Bristol-Myers Squibb position as of Q3 2026 after selling out during the quarter.
  • KEB Asset Management sold 600 Bristol-Myers Squibb shares in Q3 2026, an estimated $34.6K.
  • KEB Asset Management first reported a position in Bristol-Myers Squibb in Q4 2021 and held it in 10 quarters.
  • KEB Asset Management's Bristol-Myers Squibb position peaked at $331K in Q2 2022.
  • 2,561 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on KEB Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.